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Abstract
Topoisomerase inhibitors such as camptothecin and etoposide are used as anti-cancer drugs and induce double-strand
breaks (DSBs) in genomic DNA in cycling cells. These DSBs are often covalently bound with polypeptides at the 39 and 59
ends. Such modifications must be eliminated before DSB repair can take place, but it remains elusive which nucleases are
involved in this process. Previous studies show that CtIP plays a critical role in the generation of 39 single-strand overhang at
‘‘clean’’ DSBs, thus initiating homologous recombination (HR)–dependent DSB repair. To analyze the function of CtIP in
detail, we conditionally disrupted the CtIP gene in the chicken DT40 cell line. We found that CtIP is essential for cellular
proliferation as well as for the formation of 39 single-strand overhang, similar to what is observed in DT40 cells deficient in
the Mre11/Rad50/Nbs1 complex. We also generated DT40 cell line harboring CtIP with an alanine substitution at residue
Ser332, which is required for interaction with BRCA1. Although the resulting CtIPS332A/2/2 cells exhibited accumulation of
RPA and Rad51 upon DNA damage, and were proficient in HR, they showed a marked hypersensitivity to camptothecin and
etoposide in comparison with CtIP+/2/2 cells. Finally, CtIPS332A/2/2BRCA12/2 and CtIP+/2/2BRCA12/2 showed similar
sensitivities to these reagents. Taken together, our data indicate that, in addition to its function in HR, CtIP plays a role in
cellular tolerance to topoisomerase inhibitors. We propose that the BRCA1-CtIP complex plays a role in the nuclease-
mediated elimination of oligonucleotides covalently bound to polypeptides from DSBs, thereby facilitating subsequent DSB
repair.
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Introduction
CtIP was isolated as a binding partner of CtBP (C-terminal
binding protein), and has subsequently been shown to interact with
a number of molecules, including BRCA1 (Breast Cancer
Susceptibility Gene 1) [1]. CtIP is a functional homolog of yeast
Sae2 (Sporulation in the Absence of Spo Eleven), and acts at the
initial step of homologous recombination (HR)-dependent double-
strand break (DSB) repair [2,3]. HR is initiated by forming 39
single-strand (ss) overhangs at DSBs. In this resection step, Sae2/
CtIP works together with a complex composed of Mre11/Rad50/
Xrs2 in budding yeast, or with Mre11/Rad50/Nbs1 in mammals
[4–7]. The Rad51 recombinase protein polymerizes on the ss
DNA overhang, and the resulting ssDNA-Rad51 complex under-
goes homology search. Resection activity is upregulated by
phosphorylation of a conserved residue in Sae2 by the cyclin-
dependent kinase (CDK) [8]. This phosphorylation site is
conserved in human CtIP (Thr847), and is also phosphorylated
by CDK [7].
BRCA1 was originally identified as a tumor suppressor gene
associated with familial breast and ovarian cancer [9]. BRCA1
contains an N-terminal RING-finger domain, and is associated
with structurally related BARD1 to form an E3-ubiquitin ligase.
BRCA1/BARD1 forms three distinct complexes with Abraxas,
Bach1 and CtIP, and plays a role in DNA repair [10]. BRCA1
binds to CtIP in a manner that is dependent on the phosphor-
ylation of CtIP at Ser327 [11,12]. Following DNA damage, the
ubiquitylation of CtIP by BRCA1 causes the migration of CtIP
towards a chromatin fraction [12]. However, the biological
significance of the complex formed between BRCA1 and CtIP
has not yet been clarified.
Topoisomerases 1 and 2 (Topo1 and Topo2) have been drawing
increasing attention as important targets for cancer therapy, since
the inhibition of these enzymes causes DSBs during DNA
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replication [13]. Topo1 and Topo2 induce single-strand breaks
(SSBs) and DSBs, respectively. Covalent bonds are transiently
formed between Topo1 and the 39 end of the SSB and between
Topo2 and the 59 end of the DSB [14]. The anti-cancer agent
camptothecin (CPT) inhibits Topo1 by stabilizing the Topo1-
cleavage complex, which interferes with replication, and thereby
induces DSBs in one of the sister chromatids [15]. Topo2
inhibitors such as etoposide (VP16) and ICRF-193 also kill cycling
cells and are used in cancer therapy. VP16 stabilizes the Topo2-
cleavage complex, while ICRF-193 stabilizes the closed clamp
which forms after the strand passage [16,17]. Topo1-mediated
DNA damage caused by CPT is repaired primarily by homologous
recombination (HR), while Topo2-mediated DNA damage caused
by VP16 or ICRF-193 is mainly repaired by nonhomologous end
joining (NHEJ) [18,19]. It should be noted that the repair of CPT-
and VP16-induced DSBs requires an additional step: the
elimination of covalently bound polypeptides from the DNA ends.
Hartsuiker et al. demonstrated that Topo2 is removed from DNA
by the collaborative action of the MRX complex and ctp1 (the
ortholog of CtIP) in fission yeast [20]. It remains to be seen
whether vertebrate CtIP shares the same function as in yeast,
which does not have BRCA1 ortholog.
To understand the role of the BRCA1-CtIP interaction, we
substituted the Ser332 residue (equivalent to human Ser327) of
CtIP with alanine in the chicken DT40 B lymphocyte line [21,22].
In addition, to analyze the function of CtIP, we conditionally
depleted CtIP in DT40 cells. We here show that the depletion of
CtIP is lethal to cells as is the inactivation of Mre11, Rad50, and
Nbs1 [23,24], indicating the critical role played by CtIP in HR.
Remarkably, although the CtIP S332A mutation had no
significant impact on HR, it made cells hypersensitive to CPT
and VP16 but not to ICRF193. These observations unmasked an
unexpected function of the BRCA1-CtIP interaction: cellular
tolerance to the DSBs that are covalently associated with the
polypeptides. Our data therefore support two distinct functions of
CtIP: the resection of DSBs in HR and the elimination of
polypeptides from the cleavage complex.
Results
CtIP is required for the assembly of Rad51 at DNA
damage sites
In order to determine the function of CtIP, we conditionally
disrupted the CtIP gene in chicken DT40 cells, using a chicken
CtIP transgene under the control of a tetracycline-repressible
promoter (tetCtIP transgene, Figure S1A). We designed CtIP gene-
disruption constructs, so that the amino acid sequences from 96 to
335 would be replaced by selection-marker genes. Since the gene is
encoded on chromosome 2, which is in trisomy in DT40, we
disrupted three CtIP alleles (Figure S1B and S1C). The resulting
CtIP2/2/2tetCtIP cells tended to grow more slowly than did wild-
type cells, presumably due to overexpression of the tetCtIP transgene
(Figure 1A and 1B). To deplete the CtIP in the CtIP2/2/2tetCtIP
cells, we added doxycycline (modified tetracycline) to the culture
medium. One day after the addition of doxycycline, the amount of
CtIP was reduced to around 20% of wild-type cells (Figure 1B), and
the cells started dying as evidenced by an increase in the sub-G1
fraction (Figure 1C). This lethality can be attributed to abolished
HR, because the cells showed a significant increase in the number
of spontaneous chromosomal breaks (Table 1), as do Mre11- and
Rad51-depleted cells [23,25]. By day 3, the vast majority of the
CtIP2/2/2tetCtIP cells had stopped growing and died (Figure 1A
and 1C). We therefore conclude that CtIP is essential for
maintenance of chromosomal DNA and cellular proliferation.
To assess the HR capability of CtIP2/2/2tetCtIP cells, we
monitored the recruitment of Rad51 and RPA to DNA damage
sites one day after addition of doxycycline. Clear Rad51 foci
appeared in wild-type cells one hour after ionizing radiation (IR),
whereas Rad51 foci were hardly detectable in the CtIP-depleted
cells (Figure 2A). Likewise, the depletion of CtIP abolished the
accumulation of RPA on DNA lesions induced by microlaser
treatment (Figure 2B). This is consistent with a phenotype shown
in the previous report [3]. Thus, CtIP plays an essential role in the
resection of DSBs during HR in DT40 cells as well as in
mammalian cells.
We next investigated whether or not CtIP facilitates the
activation of BRCA1 at DSBs. To this end, we measured the
formation of conjugated-ubiquitin foci at DSBs, since Brca1
promotes extensive ubiquitylation at IR-induced DSBs [26].
Previous studies showed that BRCA12/2 DT40 cells exhibit a
prominent defect in the formation of conjugated-ubiquitin foci
[27]. In contrast, CtIP depletion did not reduce the ubiquitylation
of DNA damage sites (Figure 2C), suggesting that CtIP is not
required for the activation of Brca1.
Proficient HR in CtIPS332A/2/2 DT40 clones
To functionally analyze the interaction of CtIP with BRCA1,
we generated CtIPS332A/2/2 cells, in which the critical amino acid
in the binding interface has been mutated (Figure S2A, S2B, S2C).
The CtIPS332A/2/2 DT40 clones were capable of proliferating at a
rate similar to the CtIP+/2/2 cells without a prominent change in
the cell-cycle profile (Figure 3A and Figure S2D). Western blot
analysis showed that the S332A CtIP proteins were expressed at
the similar level to the wild-type protein, indicating that amino acid
substitutions do not affect the stability of the CtIP protein (Figure
S2E). As expected, given the results of a previous study [12], the
S332A mutation of CtIP indeed inhibited its interaction with
BRCA1 (Figure S2F).
To evaluate the capability of HR in CtIPS332A/2/2 cells, we
integrated an artificial substrate, SCneo, in the Ovalbumin locus [28],
and measured the efficiency of I-SceI-induced gene conversion.
The CtIPS332A/2/2 clones showed no significant decrease in the
Author Summary
Induction of double-strand breaks (DSBs) in chromosomal
DNA effectively activates a program of cellular suicide and
is widely used for chemotherapy on malignant cancer cells.
Cells resist such therapies by quickly repairing the DSBs.
Repair is carried out by two major DSB repair pathways,
homologous recombination (HR) and nonhomologous
end-joining. However, these pathways cannot join DSBs
if their ends are chemically modified, as seen in the DSB
ends that would arise after the prolonged treatment of the
cells with topoisomerase inhibitors such as camptothecin
and etoposide. These anti-cancer drugs can produce the
polypeptides covalently attached to the 39 or 59 end of
DSBs. It remains elusive which enzymes eliminate these
chemical modifications prior to repair. We here show
evidence that the BRCA1-CtIP complex plays a role in
eliminating this chemical modification, thereby facilitating
subsequent DSB repair. Thus, BRCA1 and CtIP have dual
functions: their previously documented roles in HR and
this newly identified function. This study contributes to our
ability to predict the effectiveness of chemotherapeutic
agents prior to their selection by evaluating the activity of
individual repair factors. Accurate prediction is crucial,
because chemotherapeutic agents that cause DNA dam-
age have such strong side effects.
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appearance of neomycin-resistant colonies compared to CtIP+/2/2
cells (Figure 3B). The proficient HR in CtIPS332A/2/2 DT40 clones
is in marked contrast to the severe phenotype of the Nbs1p70
hypomorphic mutant, which exhibited a 10-fold reduction of the
gene-targeting frequency and a 103-fold decrease in the efficiency
of HR in the SCneo substrate [29]. Next, we measured the
frequency of gene targeting at the CENP-H and Ovalbumin loci. In
contrast to I-SceI-induced gene conversion, the gene-targeting
frequency of the CtIPS332A/2/2 clones decreased moderately in
comparison with CtIP+/2/2 cells (Table 2). We speculate that this
is because unknown recombination intermediates that require
processing by CtIP/BRCA1 may arise during gene targeting event
(see Discussion).
Fluorescent immunostaining revealed that the kinetics of Rad51
focus formation after c-irradiation was indistinguishable between
CtIPS332A/2/2 cells and the CtIP+/2/2 control cells, while
BRCA12/2 cells showed the significant reduction in the Rad51
focus formation at 1–6 h after irradiation (Figure 4A). Further-
more, the CtIPS332A/2/2 mutants displayed laser-induced RPA
accumulation as did the CtIP+/2/2cells (Figure 4B). Laser-
generated RPA accumulation following BrdU incorporation
largely arises from the resection rather than other routes of single
strand formation such as the damage caused by laser itself or
replication-associated single strand formation, because RPA
accumulation is abolished specifically in Ubc13 deficient cells
[27]. This suggests that CtIPS332A/2/2 cells are proficient in
resection at DSB sites. Taken together, we conclude that the
S332A mutation of CtIP does not significantly compromise HR.
Figure 1. CtIP is essential for cell survival. (A) Defective proliferation of CtIP2/2/2tetCtIP cells following addition of doxycycline (2 mg/ml) to
deplete CtIP, from time zero. Data shown are the average results from three separate clones. Points indicate mean (n = 3); bars indicate S.D. (B)
Western blot analysis of chicken CtIP expression. Whole cell lysates were prepared from CtIP2/2/2tetCtIP cells 24 h after addition of doxycycline. b-
actin was used as a loading control. (C) Cell cycle distribution of CtIP2/2/2tetCtIP cells at the indicated time after addition of doxycycline. Cells were
pulse-labeled with BrdU for 10 min and subsequently stained with FITC-conjugated anti-BrdU antibody (Y axis, log scale) and propidium iodide (PI) (X
axis, linear scale). Each square on the left-hand side represents apoptic cells (sub-G1 fraction). The small rectangle at the bottom of the tubular arch,
the tubular arch, and the small square to the right represent cells in the G1, S, and G2/M phases, respectively.
doi:10.1371/journal.pgen.1000828.g001
Table 1. Chromosomal aberrations in CtIP2/2/2tetCtIP
mutants.
Genotype Chromatid-type Chromosome-type
IR 0 Gy Wild-type 6 9
CtIP2/2/2tetCtIPDox(2) 4 13
CtIP2/2/2tetCtIPDox(+) 7 28
IR 2 Gy Wild-type 10 24
CtIP2/2/2tetCtIPDox(2) 6 25
CtIP2/2/2tetCtIPDox(+) 20 71
c-ray irradiated (2 Gy) and non-irradiated cells were treated with colcemid for
3 h to enrich mitotic cells prior to fixation of cells for chromosome analysis.
Data are presented as the number of aberrations per 100 cells.
doi:10.1371/journal.pgen.1000828.t001
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CtIPS332A/2/2 cells display a marked hypersensitivity to
both CPT and VP16, which stabilize the Topo-cleavage
complexes
To determine the role of CtIP in the cellular response to DNA
damage, we measured the sensitivity of the CtIP mutant cells to
various genotoxic agents using a colony survival assay. CtIP+/2/2
cells exhibited the slightly elevated sensitivity toward CPT and
VP16 (Figure 5A and 5B), though they expressed the similar level of
CtIP protein to the wild-type cells (Figure S2E). It is possible that the
difference in the amount of CtIP protein between CtIP+/2/2 and
wild-type cells is too subtle to detect, and that even the suboptimal
level of CtIP protein renders the cells sensitive to genotoxic stimuli.
A compensatory post-translational regulation may be present
because CtIP+/2/2 cells exhibited about 80% reductions in CtIP
mRNA level compared to the wild-type level (Figure S2G). In
contrast to CtIP+/2/2 cells, CtIPS332A/2/2 mutants showed a
significantly increased sensitivity to VP16 and MMS (Figure 5B
and 5D), but not to c-rays (data not shown). Furthermore, the
sensitivity to CPT was dramatically elevated in the CtIPS332A/2/2
mutants, in comparison with the CtIP+/2/2 cells (Figure 5A).
The contribution of CtIP to the cellular tolerance to VP16
indicated that CtIP might play a role in NHEJ [18]. To test this
hypothesis, we evaluated NHEJ by measuring the sensitivity of
CtIP mutant cells to ICRF-193, because ICRF193-induced DNA
lesions are repaired exclusively by NHEJ, whereas a fraction of the
VP16-induced DSBs are repaired by HR [18]. The CtIPS332A/2/2
clones exhibited no increased ICRF193 sensitivity (Figure 5C).
NHEJ can also be evaluated by measuring the IR sensitivity of the
cell population at the G1 phase, where NHEJ plays a dominant
role in DSB repair [30]. The CtIP hypomorphic mutants
synchronized at the G1 phase did not show significant IR
hypersensitivity (Figure S3). These observations indicate that
Figure 2. Impaired c-ray–induced Rad51 focus formation in CtIP-depleted cells. (A) CtIP2/2/2tetCtIP cells, with or without 24 h doxycycline
treatment, were exposed to 8 Gy ionizing radiation (IR). One hour after irradiation, cells were stained with anti-Rad51 antibody. The graph shows the
quantification of Rad51 foci per cell. More than 100 cells were analyzed. (B) Accumulation of RPA protein in the cells exposed to 405 nm pulse laser.
Cells were fixed with 4% PFA 1 h post laser stimulation and stained with anti-cH2AX and anti-RPAp32 antibodies. (C) Conjugated-ubiquitin (FK2) focus
formation in wild-type (WT) or CtIP2/2/2tetCtIP DT40 cells (with or without doxycycline) at 1 h post IR (8Gy). Quantification of FK2 foci per cell is
shown in the graph. More than 100 cells were analyzed.
doi:10.1371/journal.pgen.1000828.g002
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NHEJ is not impaired in CtIPS332A/2/2 clones. In summary, in
comparison with CtIP+/2/2 cells, CtIPS332A/2/2 clones exhibited a
significantly higher sensitivity to CPT and VP16, although these
clones exhibited no decrease in the efficiency of HR or NHEJ. We
conclude that CtIP can therefore contribute to cellular tolerance to
CPT and VP16, independently of HR or NHEJ, most likely by
eliminating covalently bound polypeptides from the DSBs.
Epistatic relationship of CtIP to BRCA1 in cellular
tolerance to CPT and VP16
CtIP physically interacts with BRCA1 in a manner dependent on
phosphorylation of Ser332 [12]. In order to assess the functional
relationship between Ser332 phosphorylation of CtIP and BRCA1,
we disrupted the BRCA1 gene in the CtIPS332A/2/2 and CtIP+/2/2
clones (Figure S4A and S4B), as was done previously [31]. Both the
CtIPS332A/2/2BRCA12/2 and the CtIP+/2/2BRCA12/2 clones
proliferated with similar rates at significantly reduced growth rates,
in comparison with BRCA12/2cells (doubling time6 SD: 8.360.2 h
for wild-type, 9.360.3 h for BRCA12/2, 1160.3 h for CtIP+/2/2
BRCA12/2, 12.660.9 h for CtIPS332A/2/2BRCA12/2). The viability
of CtIPS332A/2/2BRCA12/2 cells is in marked contrast with the
lethality of CtIP-null cells, supporting the idea that the CtIP-BRCA1
interaction works independently from the function of CtIP in
resection.
We next examined the sensitivity of double mutant cells to CPT
and VP16. To this end, we measured the number of live cells after
48-hour continuous exposure to the DNA-damaging agents [32],
during which the double mutant cells are able to divide four to five
times. We did not use a conventional colony formation assay for
this purpose, because CtIP+/2/2BRCA12/2 and CtIPS332A/2/2
BRCA12/2 clones grew very badly from a single cell in semi-solid
methylcellulose medium. The number of viable cells cultured in
the presence of CPT was significantly decreased for CtIPS332A/2/2
and BRCA12/2 cells compared to the wild-type cells, whereas
CtIP+/2/2 cells grew to the similar extent to the wild-type cells in
the presence of CPT (Figure 6A). The sensitivity of CtIP+/2/2
BRCA12/2 cells to CPT was greater than that of BRCA12/2
clones. This observation is in agreement with the idea that BRCA1
and CtIP can independently contribute to HR, where CtIP
promotes the resection of DSBs, while BRCA1 subsequently loads
Rad51 at resected ssDNA overhang. Importantly, although the
CtIPS332A mutation significantly increased cellular sensitivity to
CPT in the presence of BRCA1, the CtIPS332A/2/2BRCA12/2 and
CtIP+/2/2BRCA12/2 clones exhibited a very similar sensitivity to
CPT (Figure 6A). Likewise, the CtIPS332A/2/2BRCA12/2 and
CtIP+/2/2BRCA12/2 clones exhibited indistinguishable cellular
sensitivities to VP16 (Figure 6B). These observations suggest that
CtIP and BRCA1 can act in collaboration to repair DSBs that are
chemically modified by topoisomerases.
Discussion
We here show that conditional depletion of CtIP protein led to
cellular lethality with increased frequency of chromosomal
aberrations in DT40 cells. CtIP depletion abolished the accumu-
lation of RPA and Rad51 at DNA damaged sites, suggesting that it
is required for the resection of DSBs during HR, and that this
function is essential for the proliferation of cells. These results are
in agreement with previous reports [3]. In contrast, the DT40 cells
harboring S332A mutation in CtIP showed the accumulation of
RPA and Rad51 upon DNA damage, and were able to proliferate
with normal kinetics. Remarkably, compared to the CtIP+/2/2
cells, the CtIPS332A/2/2 clones exhibited significantly increased
sensitivity to CPT and VP16, both of which stabilize the Topo-
DNA cleavage complex. These observations support the propo-
sition that, in additon to the resection of DSBs, CtIP has the
second function, most likely the removal of covalently-bound
polypeptides from DSBs. Hence, CtIPS332A/2/2 clones are the
novel separation-of-function mutants where CtIP-dependent
resection is proficient, whereas the second function required for
the tolerance to topoisomerase inhibitors is deficient.
In this study, we demonstrated that the inactivation of CtIP in
DT40 cells results in cellular death. We speculate that the defective
DSB repair during S phase is the primary cause of cellular death
rather than the misregulation of RB/E2F pathway [33,34]. It has
been reported that CtIP promotes G1/S progression by releasing
Figure 3. Proficient homologous recombination in CtIPS332A/2/2
clones. (A) Growth kinetics of the indicated CtIP mutant clones. (B) I-
Sce1–induced DSBs stimulate homologous recombination (HR) in an
artificial substrate, SCneo. The recombination frequency was calculated
by dividing the number of neomycin-resistant colonies by the number
of the total colonies. Error bars indicate S.D.
doi:10.1371/journal.pgen.1000828.g003
Table 2. Targeted integration frequencies of CtIPS332A/2/2
clones.
Targeted loci
Genotype CENP-H Ovalbumin
Wild-type 38/61 (62.2%) 24/26 (92.3%)
CtIP+/2/2 42/64 (65.6%) 25/30 (83.3%)
CtIPS332A/2/2 25/71 (35.2%) 30/47 (63.8%)
BRCA12/2 N.D. 5/37 (13.5%)
Gene-targeting efficiencies were determined by flow cytometry for CENP-H
locus and by Southern blot analysis for Ovalbumin locus. N.D. indicates not
determined.
doi:10.1371/journal.pgen.1000828.t002
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RB-imposed repression and by upregulating the genes required for
S phase entry such as cyclin D1. MEF from CtIP-deficient mice and
NIH3T3 cells transfected with CtIP siRNA arrest at G1 phase of
cell cycle. In contrast, DT40 cells that are depleted of CtIP showed
a marked reduction in S phase and an increase in sub-G1
population with the spontaneous chromosomal aberrations. We
speculate that DT40 cells have a lower threshold to enter the S
phase in the presence of DNA damage compared to the other
types of cells owing to their character that they lack p53 expression
[35] and overexpress c-myc [36].
The phenotype of our CtIP-depleted DT40 cells was remarkably
different from that of the CtIP-deficient DT40 cells generated by
Hiom’s group [37]. Surprisingly, their CtIP-depleted DT40 cells
were capable of proliferating. However, we believe that CtIP is
essential for cellular proliferation because it has been shown that
CtIP works together with Mre11/Rad50/Nbs1 complex in
budding and fission yeasts as well as in mammalian cells
[3,6,38], and the increased spontaneous chromosomal aberrations
and cellular death observed in our CtIP-depleted cells are
consistent with our previous reports that deficiency of either one
of Mre11, Rad50, or Nbs1 was all lethal to DT40 clones [23,24].
The viability of the CtIP-deficient DT40 cells generated by Hiom’s
group might be due to the occurrence of suppressor mutations
during the disruption of the three allelic CtIP genes. Another
possibility is that the disruption of exons 1 and 2 in Hiom’s group
might still allow the residual expression of an N-terminal-truncated
Figure 4. Accumulation of Rad51 and RPA at DNA damage sites is indistinguishable between CtIP+/2/2 and CtIPS332A/2/2 clones. (A)
Rad51 focus formation in CtIP mutant cells. The cells of indicated genotype were irradiated with 8Gy of c-ray, and were immuno-stained with anti-
Rad51 antibodies 1 h after irradiation. The lower graph shows the quantification of Rad51 foci per cell. More than 100 cells were analyzed. Error bars
indicate S.D. (B) The subnuclear accumulation of RPA in the cells exposed to 405 nm pulse laser. The cells were fixed with 4% PFA 1 h after exposure,
and were stained with anti-cH2AX and anti-RPAp32 antibodies.
doi:10.1371/journal.pgen.1000828.g004
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CtIP protein, as is observed for the expression of an N-terminal-
truncated Nbs1 protein in patients with Nijmegen syndrome [39].
Another critically different point between our study and Hiom’s
group is that they conclude that the phosphorylation of CtIP-S332
promotes the resection of DSBs, whereas our data do not support
this conclusion. The discrepancy between the two studies may be
attributable to the different ways of introducing the S332A
mutation into the DT40 cells. They randomly integrated wild-type
and CtIPS332A transgenes at different loci in their ‘‘CtIP-null’’ cells,
while we inserted the S332A mutant into one of the CtIP allelic
genes. This knock-in approach is essential for the accurate
quantitative evaluation of HR and NHEJ, because the endogenous
promoter expresses CtIP transcripts differently in each phase of the
cell cycle, and this differential expression accounts for the reduced
usage of HR in the G1 phase in fission yeast [38]. Alternatively, the
difference between our results could be because Hiom’s group re-
introduced human CtIP cDNA (wild type or mutants) instead of
that derived from chicken into DT40 cells to create individual
clones. The human protein may act differently or incompletely in
chicken DT40 cells.
The exact function of BRCA1 in HR is controversial. The
discovery of the BRCA1-CtIP interaction has led to a proposal
that BRCA1 might facilitate the resection step of HR [11,37,40].
However, RPA foci are not completely abolished in BRCA1
mutant cells in these reports, suggesting that ssDNA does form in
the absence of functional BRCA1. We found that RPA
accumulated at the sites of laser microirradiation in BRCA12/2
and CtIPS332A/2/2 cells, while Rad51 focus formation is impaired
in BRCA12/2 cells. These results indicate that the BRCA1-CtIP
interaction is not involved in the promotion of HR including the
resection step, and are in agreement with the idea that BRCA1
facilitates the loading of Rad51 on resected ssDNA as does
BRCA2 [1,29,41]. Recently, it was found that BRCA1 forms a
complex with BRCA2 [42], further supporting the collaborative
and overlapping function of BRCA1 and BRCA2. Although we
cannot formally exclude the possibility that the RPA accumulation
is delayed in BRCA12/2 cells (the extent of RPA accumulation
induced by laser irradiation cannot be quantified, and we failed to
induce RPA foci by other genotoxic stimuli in DT40 cells), our
data, together with the fact that BRCA1 deficiency does not lead
Figure 5. Colony survival assay of CtIPmutant cells to various genotoxic agents. Colony survival assay of asynchronous populations of cells
exposed to (A) camptothecin (CPT), (B) etoposide (VP16), (C) ICRF-193, and (D) methyl methanesulfonate (MMS). The dose is displayed on the X axis
on a linear scale, while the percent fraction of surviving colonies is displayed on the Y axis on a logarithmic scale. To count the surviving colonies, cells
were grown for 8–10 days in methylcellulose medium containing various concentrations of DNA–damaging agents. At least three independent
experiments were performed with triplicate samples, and the representative results are shown. The error bars indicate S.D.
doi:10.1371/journal.pgen.1000828.g005
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to cellular lethality in DT40 cells, indicate that BRCA1 has only a
minor role, if any, in the resection step. The discrepancies among
researchers may arise from different experimental settings
including how BRCA1 is inactivated (by gene targeting, siRNA
knockdown, or C-terminal truncation), the cell cycle distribution of
each cell type, and the extent of DSB end modifications induced
by laser or c-ray irradiation. Further studies will clarify the
differences among each group.
Accumulating evidence indicates that there are two parallel
pathways to eliminate chemical modifications from single-strand
breaks and DSBs (Figure 7). Firstly, tyrosyl-DNA phosphodiester-
ase1 (Tdp1) removes polypeptides covalently bound at the 39 end
of DSBs [43]. Polynucleotide kinase 39-phosphatase (PNKP) and
AP endonuclease I (APE1) are also involved in this process.
Likewise, PNKP, DNA polymerase b, and aprataxin remove
aberrant chemical modifications from the 59 ends of DSBs [44].
These enzymes may be capable of accurately repairing damaged
bases at DSBs. On the other hand, the second pathway involves
endonucleases and removes damaged bases along with proximal
intact oligonucleotides from the 39 or 59 ends of DSBs. Our study
showed that this pathway could contribute to cellular tolerance to
alkylating agents such as MMS as well as to topoisomerase
inhibitors.
A well-known precedent involving the second pathway is the
Mre11/Rad50/Nbs1-complex-dependent elimination of oligonucle-
otides as well as the covalently associated topoisomerase-like protein
(Spo11) from DSBs during meiotic HR in S. cerevisiae [2]. A more
recent study of the S. pombe CtIP mutant (ctp1D) showed that the level
of Top2 protein covalently bound to DNA in the ctp1D mutant
increased during treatment with TOP-53, one of the VP16
derivatives, suggesting that Ctp1 plays a role in the endonuclease-
dependent removal of covalently-bound polypeptides from the 59 end
of DSBs [20]. Our study indicates that this conclusion is also relevant
to vertebrate cells although there are significant differences between
vertebrate and yeast systems. First, yeast Ctp1 or Sae2 seem to be
important only for the removal of the peptide covalently bound to 59
of DSB ends as demonstrated for DNA damage induced by TOP-53
or Spo11 [2,20]. Second, yeast does not have BRCA1 counterpart.
BRCA1 is involved in degradation of trapped Topo1 cleavage
complexes along with proteasome [45]. We hypothesize that BRCA1
may facilitate the removal of Topo1 by degrading them to small
polypeptides, which in turn are removed with oligonucleotides by the
nuclease activity of CtIP. In summary, we here show compelling
evidence that the collaborative action of BRCA1 and CtIP plays a
critical role in the endonuclease-dependent removal of damaged
nucleotides from DSBs, and acts on the processed DSBs for
subsequent HR and NHEJ.
Materials and Methods
Cell culture
DT40 cells were cultured in RPMI-1640 medium supplemented
with 1025 M b-mercaptoethanol, penicillin, streptomycin, 10%
fetal calf serum (FCS), and 1% chicken serum (Sigma, St Louis,
MO, USA) at 39.5uC.
Generation of CtIP conditional mutant DT40 cells
To generate CtIP gene disruption constructs, genomic DNA
sequences of DT40 cells were amplified using primers 59-
GGATGCGGAGAGGCTTGAAGAGTTTTACAC-39 and 59-
TTACAGCACAACGATCACATAATCCCGCTC-39 for the 59
arm, and 59-GGAGCTTCTAGCAATACGCGGAACAACTCA-
39 and 59-GCTTCCCCTCCAATTCTTGACTGAGAATCA-39
for the 39 arm. The amplified PCR products were cloned into the
pCR2.1-TOPO vector (Invitrogen, CA, USA). The BamHI site in
the plasmid that contains the 59 arm was disrupted by blunt-self
ligation. The 1.6-kb HindIII fragment was ligated into the partially-
digested HindIII site of the 3.0-kb 39 arm containing the plasmid. A
drug-resistance gene (hisD or bsr) was inserted into the BamHI site of
the pCR2.1 vector containing both the 59 and 39 arms. To generate
CtIP+/2/2 cells, linearized CtIP gene-disruption constructs were
transfected sequentially by electroporation (BioRad). The genomic
DNA of the transfectants was digested with SacI and the targeted
clones were confirmed by Southern blot analysis. The 0.5-kb
fragment was amplified using primers 59-GATTGTATGCTTCA-
GAGGCTCCTGC-39 and 59-GAAATTCCCAACTTTAGCT-
Figure 6. Epistasis analysis of BRCA1 and CtIP in cellular tolerance to topoisomerase inhibitors. Cellular survival of each genotype was
assessed by measuring the amount of ATP in cell lysates after 48-h exposure to CPT (A) or VP16 (B). The survival curves for the CtIPS332A/2/2BRCA12/2
cells and their control CtIP+/2/2BRCA12/2 cells are depicted in red. At least five independent experiments were performed with triplicate samples, and
the representative results are shown. The error bars indicate S.D.
doi:10.1371/journal.pgen.1000828.g006
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CCCCTTGAC-39 and used as a probe. To construct the CtIP
expression plasmid, chicken the CtIP open reading frame was
amplified by PCR, using the primers 59-GGGGACAAGTTTG-
TACAAAAAAGCAGGCTTCGAACCATGAATGCGTCTGG-
GGGAACTTGTG-39 and 59-GGGGACCACTTTGTACAA-
GAAAGCTGGGTCTTATGTCTTCTGCTCTTTGCCTTTT-
GG-39, and cloned into a Gateway donor vector, pDONR207
(Invitrogen, CA, USA), by BP reaction. The CtIP gene in the donor
vector was transferred to an expression vector (pA-puro) containing
the Gateway conversion cassette under the b-actin promoter by LR
reaction. To construct a CtIP expression vector under the control of
a tetracycline-repressible promoter, CtIP cDNA was amplified by
PCR, using the primers 59-CTCGAGATGAATGCGTCTGG-
GGGAACTTGTG-39 and 59-GTCGACTTATGTCTTCTGC-
TCTTTGCCTTTTGG-39, and cloned into pCR2.1-TOPO
vector. The XhoI-SalI fragment containing the CtIP cDNA was
blunted and cloned into the EcoRV site of a modified pTRE2 vector
(Clontech, CA, USA) containing a loxP-flanked puromycin-
resistant cassette.
CtIP+/2/2 cells were introduced with the tetracycline-controlled
trans-activator (tTA) gene through retrovirus infection. Infected
cells were sub-cloned, and tTA expression was confirmed by
western blot analysis. The resulting tTA-expressing CtIP+/2/2
cells were transfected with the pTRE2 puroR/CtIP, and
puromycin-resistant clones were selected to isolate the CtIP+/2/2
tetCtIP cells. The puromycin-resistance gene was then deleted by
transiently expressing the Cre recombinase (Amaxa solution T,
program B-23). Puromycin-sensitive CtIP+/2/2tetCtIP cells were
transfected with the CtIP gene-disruption construct carrying the
puromycin-resistant cassette to generate CtIP2/2/2tetCtIP cells.
Generation of CtIPS332A/2/2 mutant cells
The targeting vectors for the CtIP S332A mutants were
generated by site-directed mutagenesis. To generate the S332A
knock-in vector, genomic DNA was amplified by PCR, using
primers 59-ATTATGCCCCTGAAAGAAGGGAAAC-39 and 59-
TTTCCTGGGTTTGCTCTTGATTTT-39, and cloned into the
pCR2.1-TOPO vector (Invitrogen, CA, USA). Site-directed
mutagenesis was performed using primers 59-GATTCTCAGG-
TAGTTGCTCCTGTTTTCGGA-39 and 59-TCCGAAAA-
CAGGAGCAACTACCTGAGAATC-39. The puromycin-resis-
tance gene was inserted into the HpaI site of the resulting plasmid.
After transfection of the S332A knock-in vector into the CtIP+/+/2
cells, the targeted clones were selected against puromycin and
then identified by Southern blot analysis of genomic DNA
digested with HindIII. To make probe DNAs, the 0.6-kb fragments
were amplified using primers 59-GACTAACAAAGATCAAC-
CTGTC-39 and 59-GTGCATGAGATTTTGGTCGTTG-39.
After the deletion of the puromycin-resistance gene by transiently
expressing Cre recombinase by nucleofection (Amaxa, Germany),
the third allele of the CtIP gene was disrupted by transfecting the
CtIP gene-disruption construct carrying the puromycin-resistance
gene. The insertion of the S332A mutation into the endogenous
CtIP gene was confirmed by RT-PCR followed by sequencing
amplified DNA.
Generation of CtIP+/2/2BRCA12/2 and
CtIPS332A/2/2BRCA12/2 clones
The puromycin-resistant cassette in the targeting vector for the
BRCA1 gene [31] was replaced with the neomycin-resistant
cassette. CtIP+/2/2 and CtIPS332A/2/2 cells were sequentially
transfected with targeting vectors containing the puromycin- and
neomycin-resistant gene, and selected against G418 and puromy-
cin, respectively. The clones with the disrupted BRCA1 gene were
identified by Southern blot analysis as described previously [31].
Real-time PCR quantification of gene expression
Quantitative real-time PCR was performed in an ABI Prism
7000 sequence detector (Applied Biosystems) using SYBR Green
PCR Master Mix reagent (Applied Biosystems) according to the
manufacturer’s instruction. CtIP cDNA was amplified using
primers 59-GGAATTGGAGGAGCAAAAGCAAC-39 and 59-
GAAACTCACTGTTGCTCTTTG-39. The expression level of
Figure 7. Model for processing the modified DNA ends. Topoisomerase inhibitors induce chemical modification (indicated by a circle) at 39
and 59 ends of DSBs, and thereby inhibit subsequent DSB repair. There are two distinct pathways to eliminate such chemical modifications from DSBs.
In the first pathway, tyrosyl-DNA phosphodiesterase1 (Tdp1), polynucleotide kinase 39-phosphatase (PNKP), and AP endonuclease I (APE1) remove
various chemical modifications from the 39 ends of DSBs, while PNKP, DNA polymerase b (Polb), and aprataxin (APTX) remove those from the 59 ends
of DSBs (the arrows on the left). In the second pathway, MRN-CtIP-BRCA1 may act as an endonuclease and eliminate oligonucleotides covalently
bound to polypeptide (the arrows on the right). The resulting processed DSBs are subject to homologous recombination (HR) and nonhomologous-
end-joining (NHEJ)-dependent DSB repair.
doi:10.1371/journal.pgen.1000828.g007
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CtIP was normalized against b-actin using the comparative CT
method.
Western blotting analysis
For Western blot analysis, the antibodies specific for CtIP
(BL1914, Bethyl, TX, USA), b-actin (Sigma, MO, USA), Rad51
(Ab-1, Calbiochem, CA, USA) were used for detection of each
protein. Secondary antibodies were horseradish peroxidase (HRP)-
conjugated antibodies to mouse Ig (GE Healthcare, MA, USA) and
HRP-conjugated antibody to rabbit Ig (Santa Cruz, CA, USA).
Chromosome aberration analysis
Karyotype analysis was performed as described previously [25].
To measure the number of c-ray-induced chromosome breaks in
mitotic cells, we exposed cells to 2 Gy c-rays and immediately
added colcemid. At 3 hours after irradiation, mitotic cells were
harvested and subjected to chromosome analysis.
Measurement of cellular sensitivity to DNA–damaging
agents
Methylcellulose colony formation assays were performed as
described previously [30,46]. Since in this assay the plating
efficiency of BRCA1-deficient cells was less than 50%, we used a
different assay to measure cellular sensitivity to DNA-damaging
agents. Cells (16103) were seeded into 24-well plates containing
1 ml culture medium per well and the DNA-damaging agents, and
then incubated at 39.5uC for 48 hours. To assess the number of
live cells, we measured the amount of ATP in the cellular lysates.
We confirmed that the number of live cells was closely correlated
with the amount of ATP. This ATP assay was carried out with 96-
well plates using a CellTiter-Glo Luminescent Cell Viability Assay
Kit (Promega Corporation, WI, USA). Briefly, we transferred
100 ml of cell suspension to the individual wells of the plates,
placed the plates at room temperature for approximately
30 minutes, added 100 ml of CellTiter-Glo Reagent, and mixed
the contents for 2 minutes on an orbital shaker to induce cell lysis.
The plate was then incubated at room temperature for 10 minutes
to stabilize the luminescent signal. Luminescence was measured by
Fluoroskan Ascent FL (Thermo Fisher Scientific Inc., MA, USA).
I-Sce-I–induced gene conversion and targeted
integration frequencies
The measurement of homologous recombination frequencies
using a SCneo cassette [28] and CENP-H-EGFP was performed as
described previously [47]. After the I-Sce-I vector was transfected
into the cells, the frequency of neomycin-resistant colony
formation was measured.
Synchronization of cells
To enrich DT40 cells in the G1 phase, cells were synchronized
by centrifugal counterflow elutriation (Hitachi Industrial, Japan).
The cell suspension (,56107) was loaded at a flow rate of 11 ml/
min into an elutriation chamber running at 2,000 rpm. The first
50 ml was discarded, and the following 100 ml was used as a G1-
phase cell fraction.
Microscopy imaging and generation of DNA damage
Fluorescence microscopy was carried out and images were
obtained and processed using the IX81 (Olympus, Japan). Cells
were cultured in medium containing BrdU (10 mM) for 24–48 h to
sensitize them to DSB generation by means of a 405 nm laser from
a confocal microscope (FV-1000, Olympus, Japan). During laser
treatment, cells were incubated in phenol red-free Opti medium
(GIBCO, NY, USA) to prevent the absorption of the laser’s
wavelength. c-irradiation was performed using 137C (Gammacell
40, Nordion, Kanata, Ontario, Canada). Antibodies against
Rad51 (Ab-1, Calbiochem, CA, USA), FK2 (Nippon Biotest
Laboratories, Japan), RPA p32 (GeneTex, TX, USA), rabbit Ig
(Alexa 488-conjugated antibody, Molecular Probe, OR, USA),
and mouse Ig (Alexa 594-conjugated antibody, Molecular probe,
OR, USA) were used for visualization.
Supporting Information
Figure S1 Generation of CtIP2/2/2tetCtIP mutants. (A) CtIP gene
disruption strategy. The map shows the organization of the CtIP gene
(top), targeting construct (middle), and targeted allele (bottom). Black
and white boxes represent exons and the drug-marker cassettes,
respectively. (B) Genomic PCR analysis at the disrupted site using
primers p1 and p2, as shown in (A). (C) Southern blot analysis of SacI-
digested genomic DNA using the probe shown in (A).
Found at: doi:10.1371/journal.pgen.1000828.s001 (11.61 MB
TIF)
Figure S2 Generation of CtIPS332A/2/2 mutants. (A) The
strategy for the generation of CtIPS332A/2/2 mutants. The
knock-in vectors shown in Figure S3B were introduced into the
CtIP+/+/2 cells. The insertion of the S332A mutation was verified
by Southern blot analysis of HindIII-digested genomic DNA.
Cre recombinase were transiently expressed in the resulting
CtIPS332A/+/2 clones to delete the drug-resistant marker. The
remaining intact CtIP allele was targeted by the CtIP disruption
construct to obtain CtIPS332A/2/2 clones. (B) The knock-in
constructs for the generation of CtIPS332A/2/2 mutant clones.
Black and white boxes represent exons and the drug-marker
cassettes, respectively. (C) Nucleotide sequence analysis of CtIP
cDNAs derived from the CtIP+/2/2 and CtIPS332A/2/2 mutant.
The total RNA was subjected to reverse transcription. The regions
spanning the mutations were amplified by PCR and the sequence
was determined. (D) Cell cycle profiles of CtIPS332A/2/2 and
CtIPF871A/2/2 mutant cells. Cells were pulse-labeled with BrdU
for 10 min and subsequently stained with FITC-conjugated anti-
BrdU antibody (Y axis, log scale) and propidium iodide (PI) (X
axis, linear scale). (E) Western blot analysis of wild-type, CtIP+/2/2
and CtIPS332A/2/2 DT40 clones. b-actin was used as a loading
control. (F) FLAG-BRCA1 association with CtIP is dependent on
Ser332. 293T cells were transfected with plasmids encoding
FLAG-tagged chicken BRCA1 together with either wild-type CtIP
or S332A CtIP. Cell lysates were subjected to immuno-
precipitation with anti-FLAG antibody, and the precipitated
proteins were detected with anti-FLAG or anti-CtIP antibody.
(G) Quantitative real time PCR of CtIP mRNA in wild-type,
CtIP+/2/2 and CtIPS332A/2/2 DT40 clones. PCR amplification
was performed in triplicate. The expression level of CtIP was
normalized against b-actin using the comparative CT method.
Found at: doi:10.1371/journal.pgen.1000828.s002 (19.89 MB
TIF)
Figure S3 Sensitivity of CtIPS332A/2/2 mutant to IR at G1
phase. Cells at G1 phase were separated by centrifugal elutriation
and were c-irradiated for colony survival assay. The dose of c-ray
irradiation is displayed on the X axis on a linear scale, while the
percent fraction of surviving colonies is displayed on the Y axis on
a logarithmic scale.
Found at: doi:10.1371/journal.pgen.1000828.s003 (10.15 MB
TIF)
Figure S4 Generation of CtIP+/2/2BRCA12/2 and CtIPS332A/2/2
BRCA12/2 mutants. (A) Southern blot analysis of double mutant
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clones. The genomic DNA of indicated genotype was digested with
HindIII and hybridized with the probe which detects the 39 of the
targeted BRCA1 site. The top band at 10 kb and the bottom band at
4.5 kb correspond to the BRCA1 allele disrupted with neomycin
(NEO)- and puromycin (Puro)-resistance cassette, respectively. The
middle band at 5.7 kb is the non-targeted internal allele of BRCA1
gene. (B) RT–PCR of double mutant clones. cDNA was synthesized
from each genotype and was used for PCR amplification of BRCA1
(upper panel) or b-actin (lower panel) as a control.
Found at: doi:10.1371/journal.pgen.1000828.s004 (7.59 MB
TIF)
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